Contact Support
The next-generation closed-system drug transfer device (CSTD) solution for hazardous drug protection
Safety. Performance. Ergonomics. Ease of use. We've optimized every component, and the result is a CSTD with design innovations that advance hazardous drug safety. The BD PhaSeal™ Optima system meets the requirements of the NIOSH IPA draft CSTD-test protocol‡, a robust test protocol applicable to barrier-type closed system drug transfer devices.1,2
Every component is designed with no inlets or air exchange for completely airtight hazardous drug transfers
The BD PhaSeal™ Optima system prevents microbial ingress for up to 168 hours and 10 penetrations*†
The BD PhaSeal™ Optima system minimizes residual drug loss in vials compared to other similar systems
Feedback from longstanding CSTD users and traditional technique users guided us to optimize and innovate the design
Safety
Performance
Ergonomics
Ease of use
BD PhaSeal™ Optima System | |||
---|---|---|---|
Catalog no. | Product | ||
515052 | Injector N35-O | ||
515053 | Injector N35-O multipack | ||
515060 | Protector P13-O | ||
515064 | Protector P20-O | ||
515065 | Protector P20-O multipack | ||
515070 | Connector C35-O | ||
515078 | Infusion adapter C100-O | ||
515079 | Infusion adapter C100-O multipack | ||
515085 | Infusion clamp M25-O | ||
515082 | Assembly fixture M12-O |
Please note, not all products, services or features of products and services may be available in your local area. Please check with your local BD representative.
‡2015
*Within an ISO Class V environment following aseptic technique.
†The ability to prevent microbial ingress for up to 168 hours should not be interpreted as modifying, extending or superseding a manufacturer's labeling recommendations for the storage and expiration dating of the drug vial. Refer to drug manufacturer’s recommendations and USP compounding guidelines for shelf life and sterility information.
BD-20816